PENETREX
LOE ApproachingNDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PENETREX is an oral small-molecule tablet approved in 1991 by Sanofi with an unknown mechanism of action and indication profile. The drug's specific therapeutic target and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing or reallocation to pipeline assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PENETREX currently has zero linked job openings, reflecting its LOE-approaching status and stable, low-growth market position. Careers on this product are most relevant for commercial professionals managing the transition from branded to generic competition rather than launch or growth-stage roles.
Brand ManagerField Sales Representative
Worked on PENETREX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.